Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease
Open Access
- 6 May 2020
- journal article
- research article
- Published by Elsevier BV in Neurobiology of Disease
- Vol. 141, 104892
- https://doi.org/10.1016/j.nbd.2020.104892
Abstract
No abstract availableFunding Information
- CIBERNED (CB06/05/0055 (RM), PI2018/01-3 (JF-R), CB06/05/0089)
- MINEICO (SAF2016-78207-R, PCIN-2015-098, SAF2015-68580-C2-1-R)
- Instituto de Salud Carlos III (PNSD2016I033)
- Ramón Areces Foundation (172275)
- GW Research Ltd
- E “Enhancing Mobility between Latin American and Caribbean countries and Europe”
- Complutense University-Predoctoral Programme
This publication has 76 references indexed in Scilit:
- The cannabinoid agonist WIN55212-2 decreases l-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated ratsNeuroscience Research, 2012
- Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptorsNeurobiology of Aging, 2011
- Symptom‐relieving and neuroprotective effects of the phytocannabinoid Δ9‐THCV in animal models of Parkinson's diseaseBritish Journal of Pharmacology, 2011
- Enhanced striatal cholinergic neuronal activity mediatesl-DOPA–induced dyskinesia in parkinsonian miceProceedings of the National Academy of Sciences of the United States of America, 2010
- Selective Vulnerability in Striosomes and in the Nigrostriatal Dopaminergic Pathway After Methamphetamine AdministrationNeurotoxicity Research, 2009
- WIN55,212‐2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine mouse model of Parkinson’s diseaseEuropean Journal of Neuroscience, 2009
- The endocannabinoid system as a target for the treatment of motor dysfunctionBritish Journal of Pharmacology, 2009
- The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarinBritish Journal of Pharmacology, 2008
- Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: Role of CB1 and TRPV1 receptorsExperimental Neurology, 2007
- Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson’s diseaseNeurobiology of Disease, 2007